proportion of pharmacists) expected benefits regarding industry outcomes; compared with only 20% of specialists. Almost all pharmacists mentioned price related benefits overall (98%), with greatest focus on for the in ten pharmacists also expected benefits in terms ‘more affordable PBS’ (80%). Seven of pharmacy business (71%), in terms of and stock holding ‘larger profit margins’ (62%) ‘lower costs’ (52%). Table 7: Potential benefits to prescribing/dispensing biosimilar medicines Community Specialists General practitioners pharmacists (n=170) % (n=71) % (n=87) % Price related - total 99 86 98 Lower prices through 88 66 47 competition More affordable for the 84 61 80 PBS Save taxpayers money 84 55 59 More affordable for 74 51 43 hospitals More affordable for 58 59 61 patients Enables more 58 51 66 medicines to be listed on the PBS Patient outcomes - 59 82 75 total Broadens access for 39 45 39 patients at an earlier stage of disease Treatment choice 28 52 26 Mitigate against 26 28 52 medicine shortages Positive impact on 14 44 30 patient outcome Industry outcomes - 20 37 34 total Advances in medicine 16 31 32 technology Improved 8 18 11 manufacturing processes Pharmacy business - - 71 outcomes - total Larger profit margin for - - 62 pharmacies Lower stock holding - - 52 costs for pharmacies
proportion of pharmacists) expected benefits regarding industry outcomes; compared with only 20% of specialists. Almost all pharmacists mentioned price related benefits overall (98%), with greatest focus on ‘more affordable for the PBS’ (80%). Seven in ten pharmacists also expected benefits in terms of pharmacy business (71%), in terms of ‘larger profit margins’ (62%) and ‘lower stock holding costs’ (52%). Table 7: Potential benefits to prescribing/dispensing biosimilar medicines Specialists (n=170) % General practitioners (n=71) % Community pharmacists (n=87) % Price related - total 99 86 98 Lower prices through competition 88 66 47 More affordable for the PBS 84 61 80 Save taxpayers money 84 55 59 More affordable for hospitals 74 51 43 More affordable for patients 58 59 61 Enables more medicines to be listed on the PBS 58 51 66 Patient outcomes - total 59 82 75 Broadens access for patients at an earlier stage of disease 39 45 39 Treatment choice 28 52 26 Mitigate against medicine shortages 26 28 52 Positive impact on patient outcome 14 44 30 Industry outcomes - total 20 37 34 Advances in medicine technology 16 31 32 Improved manufacturing processes 8 18 11 Pharmacy business outcomes - total - - 71 Larger profit margin for pharmacies - - 62 Lower stock holding costs for pharmacies - - 52